STOCKHOLM, Jan. 31,
2023 /PRNewswire/ -- During January, Calliditas
Therapeutics AB (publ) has issued 7,500 common shares connected to
the company's long term incentive program 2019/2022. Thus, as of
January 31, 2023, the number of
shares and votes in the company amounts to 59,580,087 shares and
59,580,087 votes.
For further information, please contact:
Mikael Widell, Investor
relations
Tel.: +46 703 11 99 60, email: mikael.widell@calliditas.com
The information in the press release is such that Calliditas
Therapeutics AB (publ) is required to disclose pursuant to the
Swedish Financial Instruments Trading Act. The information was
submitted for publication, through the agency of the contact
persons set out above, at 08:00 CET
on January 31, 2023.
About Calliditas
Calliditas Therapeutics is a commercial stage biopharma company
based in Stockholm, Sweden focused
on identifying, developing and commercializing novel treatments in
orphan indications, with an initial focus on renal and hepatic
diseases with significant unmet medical needs. Calliditas' lead
product, developed under the name Nefecon, has been granted
accelerated approval by the FDA under the trade name
TARPEYO® and conditional marketing authorization by the
European Commission under the trade name Kinpeygo®.
Additionally, Calliditas is conducting a Phase 2b/3 clinical trial in primary biliary
cholangitis and a Phase 2 proof-of-concept trial in head and neck
cancer with its NOX inhibitor product candidate, setanaxib.
Calliditas' common shares are listed on Nasdaq Stockholm (ticker:
CALTX) and its American Depositary Shares are listed on the Nasdaq
Global Select Market (ticker: CALT).
The following files are available for download:
|
https://mb.cision.com/Main/16574/3705881/1815153.pdf
|
Number of shares and
votes January 2023 (Eng)
|
View original
content:https://www.prnewswire.com/news-releases/number-of-shares-and-votes-in-calliditas-therapeutics-301734370.html
SOURCE Calliditas Therapeutics